An open randomised study to assess the efficacy of gatifloxacin versus chloramphenicol for the treatment of uncomplicated typhoid fever in Kathmandu, Nepal

ISRCTN	ISRCTN53258327
DOI	https://doi.org/10.1186/ISRCTN53258327
Secondary identifying numbers	061330; OXTREC 002-06

Submission date: 11/04/2006
Registration date: 11/04/2006
Last edited: 20/03/2013

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Infections and Infestations

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Dr Buddha Basnyat
Scientific

Patan Hospital
Kathmandu
-
Nepal

Phone	+977 (0)1 44 34642/18774
Email	rishibas@wlink.com.np

Study information

Study design	Randomised controlled trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Not specified
Study type	Treatment
Scientific title
Study acronym	ED
Study hypothesis	There has been a steady change in Kathmandu in the sensitivity of Salmonella typhi (the bacteria that causes typhoid fever) to all antibiotics. In Kathmandu in 2005 less than 5% of isolates are resistant to first line antibiotics including Chloramphenicol but they do show significantly poorer clinical response to the older fluoroquinolones (Ciprofloxacin and Ofloxacin) with high rates of Nalidixic acid resistance. There has been interest in Kathmandu and in the Indian Sub-Continent about returning to the use of the classical antibiotics for typhoid including Chloramphenicol. It is unclear in this environment, whether this is a reliable therapy for enteric fever or whether Gatifloxacin, a new generation and affordable floroquinolone, would be the better choice.
Ethics approval(s)	Not provided at time of registration
Condition	Typhoid fever
Intervention	Gatifloxacin versus Chloramphenicol. Added as of 20/09/2007: This trial was stopped temporarily in September 2006 at the request of the Nepal Health Research Council and Department of Drug Administration after the reports of dysglycaemia associated with gatifloxacin. The trial was resumed on Dec 2006 after the ethical committee and the Drug Administration authority were assured that dysglycaemia was not a problem in the young population who are most affected by enteric fever and all the patients in the trial were monitored closely for any dysglycaemia by fingerprick glucose testing. Please note that due to the reasons stated above, the anticipated end date of this trial has changed. The previous end date of this trial was 30th April 2007.
Intervention type	Drug
Pharmaceutical study type(s)
Phase	Not Specified
Drug / device / biological / vaccine name(s)	Gatifloxacin, Chloramphenicol
Primary outcome measure	Failure of treatment defined as the occurrence of any one of the following: 1. Persistent fever at day ten of treatment 2. Failure to clear completely the admission symptoms at day ten 3. Blood culture positive at day ten of treatment 4. Need for 'rescue' treatment with ceftriaxone 5. Culture confirmed relapse within 28 days of starting therapy 6. The development on treatment of any complication: 6.1 Clinically significant bleeding 6.2. Fall in the Glasgow Coma Score 6.3. Perforation of the gastrointestinal tract 6.4. Admission to hospital within 28 days of starting therapy
Secondary outcome measures	No secondary outcome measures
Overall study start date	01/05/2006
Overall study end date	30/06/2008
Reason abandoned (if study stopped)	This trial was stopped in September 2006 but has since restarted again (see interventions for more details of this - 20/09/07). In the light of the reports on dysglycaemia in elderly patients in North American the Dept of Drug Administration (DDA) in Nepal have asked us to provide some additional information on Gatifloxacin. Whilst providing this additional information and following discussion with the DDA and the Nepal Health Research Council, we have suspended the study. As the investigators, we have had no cause for concern during the study and have not identified any problems with glycaemic control on history taking, regular blood glucose monitoring and during the follow up of the study. We are in the process of providing the additional information requested and will let you know of the decision of the DDA as soon as we know of it. We hope that we will be able to restart the study following their recommendation. At the time of suspension we have recruited 404 patients, 180 with confirmed enteric fever. As a randomised study we do not feel that the suspension has an impact on the study conduct whilst we wait for the decision.

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	Both
Target number of participants	320
Participant inclusion criteria	Any patient with suspected uncomplicated enteric fever who gives consent.
Participant exclusion criteria	1. No consent 2. Pregnancy
Recruitment start date	01/05/2006
Recruitment end date	30/06/2008

Locations

Countries of recruitment

Nepal

Study participating centre

Patan Hospital

Kathmandu
-
Nepal

Sponsor information

University of Oxford (UK)
University/education

University Offices
Wellington Square
Oxford
OX1 2JD
England
United Kingdom

Phone	+44 (0)1865 270143
Email	research.services@admin.ox.ac.uk
Website	http://www.ox.ac.uk
"ROR"	https://ror.org/052gg0110

Funders

Funder type

Charity

The Wellcome Trust (UK) (grant ref: 061330)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2011		Yes	No